Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Kaempferol – A dietary anticancer molecule with multiple mechanisms of action: Recent trends and advancements

Dharambir Kashyap a, Ajay Sharma b, Hardeep Singh Tuli c,*, Katrin Sak d, Sandeep Punia c, Tapan K. Mukherjee c

a Department of Histopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab 160012, India
b Department of Chemistry, Career Point University, Tikker - Kharwarian, Hamirpur, Himachal Pradesh 176041, India
c Department of Biotechnology, Maharishi Markandeshwar University, Mullana-Ambala, Haryana, India
d NGO Praeventio, Tartu, Estonia

Article info

Article history:
Received 12 May 2016
Received in revised form 1 January 2017
Accepted 9 January 2017
Available online 18 January 2017

Keywords:
Kaempferol
Anti-proliferative
Anti-metastasis
Anti-angiogenesis
Anti-inflammation
Synergism

Abstract

The consumption of diet-based naturally bioactive metabolites is preferred to synthetic material in order to avert health-associated disorders. Among the plant-derived polyphenols, kaempferol (KMF) is considered as a valuable functional food ingredient with a broad range of therapeutic applications such as anti-cancer, antioxidant and anti-inflammatory uses. KMF acts on a range of intracellular as well as extracellular targets involved in the cell signaling pathways that in turn are known to regulate the hallmarks of cancer growth progressions like apoptosis, cell cycle, invasion or metastasis, angiogenesis and inflammation. Importantly, the understanding of mechanisms of action of KMF-mediated therapeutic effects may help the scientific community to design novel strategies for the treatment of dreadful diseases. The current review summarizes the various types of molecular targets of KMF in cancer cells as well as other health-associated disorders. In addition, this review also highlights the absorption, metabolism and epidemiological findings.

© 2017 Elsevier Ltd. All rights reserved.
1. Introduction

The interest of scientific community to identify and characterize bioactive constituents from various plant extracts for suitable use in pharmaceutical industry or in composition of functional foods is significantly increasing. Today, it is generally accepted that nutrition plays an important role in the prevention of different chronic diseases and decreasing the risk factors by virtue of its functional ingredients. Among the broad category of plant-derived bioactive compounds, flavonoids are found to possess multiple health benefits. Therefore they are being considered as a medicinally important class of dietary molecules (Ravishankar, Rajora, Greco, & Osborn, 2013). These plant-based secondary metabolites are known to represent a number of structurally diverse classes of polyphenols with potential pharmacological activities, including anticancer, anti-inflammatory, antioxidant, and anti-pathogenic properties (Rajendran et al., 2014; Ravishankar et al., 2013). Indeed, numerous in vitro and in vivo studies have reported the ability of flavonoids to interfere in different stages of carcinogenesis like migration, invasion, metastasis, and angiogenesis (Ravishankar et al., 2013). Moreover, epidemiological studies have shown that long-term and regular consumption of dietary items rich in flavonoids, such as fruits and vegetables, are associated with the lower risk of malignancy developments (Batra & Sharma, 2013; Kozlowska & Szostak-Wegierek, 2014; Tena et al., 2013). The daily intake of flavonoids among humans is still greatly variable, ranging from about twenty milligrams to virtually one gram (Jaramillo-Carmona et al., 2014). Although, flavonoids are characterized by a common skeleton of diphenyl propane, they can be further subdivided into flavanols, flavonones, flavones, isoflavones and anthocyanins based on the peculiarities in their chemical structures (Batra & Sharma, 2013; Kozlowska & Szostak-Wegierek, 2014; Sak, 2014; Tena et al., 2013).

Kaempferol (KMF), a well characterized natural flavonol, is present in 80% of plant-based foods, including broccoli, kale, cabbage, leek, tomato, beans, grapes, strawberries, apples, and tea (Chen & Chen, 2013; Chen et al., 2013; Jaramillo-Carmona et al., 2014; Kim & Choi, 2013; Rajendran et al., 2014). It has been reported that KMF has potential to significantly modulate a variety of signaling pathways that are involved in many adverse clinico-pathological conditions (Batra & Sharma, 2013; Chen & Chen, 2013; Jaramillo-Carmona et al., 2014; Kim & Choi, 2013; Rajendran et al., 2014). In contrast to the standard chemotherapeutic drugs utilized in cancer treatment at present, KMF showed minimal side effects evidenced in the different experiments along with its effective synergistic ability in combination with various synthetic cytotoxic drugs (Chen & Chen, 2013; Chen et al., 2013; Kim & Choi, 2013; Rajendran et al., 2014). However, essential efforts are still needed to uncover its unexplored health benefits. This review highlights the multiple molecular targets of KMF that are involved in a variety of cellular signaling pathways. In addition to this, the review also discusses synergistic studies of KMF with other known therapeutic drugs along with its pharmacokinetics and epidemiological findings.

2. Chemistry and source of kaempferol

Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one) was initially discovered in Camellia sinensis (tea tree) and is abundant in different genera of plants such as Capparis spinosa (Capers) and Crocus sativus (Saffron) (Calderon-Montano, Burgos-Moron, Perez-Guerrero, & Lopez-Lazaro, 2011; Devi et al., 2015; Mercader-Ros et al., 2013, chap. 1). Table 1 summarizes the list of all sort of natural sources of KMF (see Fig. 1).

2.1. Biosynthetic preview

The biosynthetic approach of KMF is known to involve the condensation of cinnamoyl-CoA (1) and malonyl-CoA (2) in the presence of chalcone synthase, a catalytic enzyme, which results in the formation of naringenin-chalcone (3). Chalcone has been considered as the most widely studied precursor for a variety of flavonol synthesis. Further, chalcone isomerase mediates isomerisation reactions and leads to the formation of naringenin (flavanone) (4). In the next step, the hydroxylation is known to occur at C3 position of naringenin by flavanone 3-dioxygenase which leads to the synthesis of dihydrokaempferol (5). In the last step, flavonol synthase mediated exordium of a double bond at the C2–C3 position occurs in the dihydrokaempferol skeleton which results in the formation of KMF (Devi et al., 2015) (Fig. 2).

Naturally, KMF is also known to exist in conjugate forms with different sugar molecules such as rutinose, rhamnose, glucose and galactose that cause the formation of glycosidic combinations of KMF, such as astragalin (kaempferol-3-O-glucoside), kaempferol-3-beta-D-galactoside, kaempferol-3-rutinoside. Besides these, other derivatives, such as kaempferol methyl ether, kaempferol dimethyl ether, kaempferol trimethyl ether and kaempferol sulphate have also been noted (Calderon-Montano et al., 2011; Murakami & Tanaka, 1988).

2.2. Chemical synthesis

Chemically, KMF is synthesized by complex reaction having many steps: (a) cross aldol condensation of 2,4,6-trimethoxyacetophenone (6) and 4-methoxybenzaldehyde (7) with KOH, (b) ortho-demethylation of 2,4,6,4'-tetramethoxychalcone (8) in the presence of AlCl3, (c) I2-mediated oxidative cyclization of 2-hydroxy-4,6,4'-trimethoxychalcone (9), (d) methylation of 5-hydroxy-7-methoxy-2-(4-methoxyphenyl)chromen-4-one by MeSO4 (10), (e) oxidative hydroxylation of 5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (11) catalysed by DDO, (f) BBr3 controlled catalytic demethylation of 3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one (12) (Lee & Wu, 2001) (Fig. 3A).

Another convenient method for KMF synthesis involves the reaction of o-benzoylxylophloracetophenone (13), p-(acetylxy) benzoic anhydride (14), sodium p-acetoxylbenzoate (15) in the presence of triethylamine at 160–165 °C for 8 h, followed by mechanical stirring and aqueous KOH treatment that results in the formation of desired product (Ichikawa, Pamukcu, & Bryan, 1982) (Fig. 3B).

3. Therapeutic effects of kaempferol

3.1. Cell cycle arrest and apoptosis by kaempferol

Recent in vitro and in vivo studies have shown the antiproliferative and proapoptotic activities of KMF against various types of cancers including breast (Azevedo et al., 2015; Kim, Hwang, & Choi, 2016; Liao et al., 2016), ovarian (Luo, Rankin, Li, Depriest, & Chen, 2011), lung (Kuo et al., 2015), pancreas (Zhang, Chen, Li, Chen, & Yao, 2008), esophagus (Yao et al., 2016), stomach (Song et al., 2015), colon (Cho & Park, 2013), prostate (Halimah et al., 2015), bladder (Dang et al., 2015), kidney (Song et al., 2014) and others. Most of these studies demonstrate that the mechanism of KMF is dependent on the inhibition of proliferation of various cancer cells either via cell cycle arrest or induction of apoptosis (Kuo et al., 2015; Liao et al., 2016). KMF-dependent inhibition of cancer proliferation is mediated through arrest of the different phases of cell cycle (Fig. 4) and inhibition of cell cycle transition points.
### Table 1
An overview about the sources of KMF and its derivatives.

| S. no | Derivatives | Plant sources |
|-------|-------------|---------------|
| 1.    | Kaempferol  | *Macrothelypteris torresiana* Ching var. *calvata* Holtt.  
      |             | *Notholaena standleyi* Maxon  
      |             | *Osmunda cinnamomea* L. var. *asiatica* Fern.  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Notholaena standleyi* Maxon  
      |             | *Osmunda cinnamomea* L. var. *asiatica* Fern.  
      |             | *Pityrogramma triangulifera* Holtt. |
| 2.    | Kaempferol 4′-methyl ether | *Asplenium diplazisorum* Hieron  
      |             | *Notholaena standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Cheilanthes albo-marginata* Clarke |
| 3.    | Kaempferol 7-methyl ether | *Cheilanthes farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 4.    | Kaempferol 3-methyl ether | *Cheilanthes farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 5.    | Kaempferol 5-methyl ether | *Cheilanthes farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 6.    | Kaempferol 3-sulphate | *Adiantum capillus-veneris* L.  
      |             | *Cheilanthes farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 7.    | Kaempferol 7,4′-dimethyl ether | *Cheilanthes farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 8.    | Kaempferol 3,4′-dimethyl ether | *Cheilanthes farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 9.    | Kaempferol 3,7-dimethyl ether | *Cheilanthes albo-marginata* Clarke  
      |             | *C. farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 10.   | Kaempferol 3,7,4′-trimethyl ether | *Cheilanthes farinosa* Kif  
      |             | *C. grisea* Blank  
      |             | *C. kaufussii* Kze.  
      |             | *N. nivea* Desv.  
      |             | *N. standleyi* Maxon  
      |             | *Pityrogramma triangulifera* Holtt.  
      |             | *Maxon var. triangulifera* Holtt. |
| 11.   | Kaempferol 3-O-β-D-glucoside | *Acrophorus nodosus* Pro  
      |             | *Adiantum aethiopicum* L.  
      |             | *A. capillus-veneris* L.  
      |             | *A. cuneatum* Langsd.  
      |             | *A. monochlamys* D.C. Eaton  
      |             | *Absophila spiniulosa* Christella acuminata Lev.  
      |             | *C. para-sativa* Lev.  
      |             | *Cytathe contamianus* Copel.  
      |             | *C. hancockii* Copel.  
      |             | *C. leichhardtiana* Copel.  
      |             | *C. mertensiana* Copel.  
      |             | *C. podophylla* Hook.  
      |             | *Cystopteris fragilis* Bernh  
      |             | *Davallia divaricata* Bl.  
      |             | *Denstreaudia scabra* Moore  
      |             | *D. wilfordii* Christ  
      |             | *Hypodematiurn crenatum* Kuhn  
      |             | *H. furiei* Tagawa  
      |             | *Onoclea sensibilis* L. var. *interrupta* Maxim.  
      |             | *Osmunda cinnamomea* L. var *asiatica* Fern.  
      |             | *Peranema cyanographoides* Don  
      |             | *Pitynomades scopendria* Ching  
      |             | *Plagiogyria matsumureana* Makino  
      |             | *Wagneriopteris nipponica* Loeve et Loeve  
      |             | *Athrythium filix-femina* Roth  
      |             | *Ceterach officinarum* DC  
      |             | *Cystopteris fragilis* Bernh.  
      |             | *Cystopteris fragilis* Bernh.  
      |             | *Athrythium filix-femina* Roth  
      |             | *Acystopteris japonica* Nakai  
      |             | *Osmunda cinnamomea* L. var. *asiatica* Fern  
      |             | *Wagneriopteris nipponica* Loeve et Loeve  
      |             | *Platycereus scolopendria* Ching  
      |             | *Pteris crenata* Linn.  
      |             | *Pteris cretica* Linn.  
      |             | *Pteris minor* Willd.  
      |             | *Pteris marginata* Lind.  
      |             | *Pteris multifida* Lind.  
      |             | *Pteris ovata* Lind.  
      |             | *Pteris militarii* Linn.  
      |             | *Pteris neglecta* Lind.  
      |             | *Pteris pinnata* Lind.  
      |             | *Pteris sagittata* Lind.  
      |             | *Pteris undulata* Lind.  
      |             | *Pteris versicolor* Lind.  
      |             | *Pteris vittata* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lind.  
      |             | *Pteris yaku-pyrene* Lin
including G0/G1 transition in esophage squamous cell carcinoma (Yao et al., 2016) or G2/M transition in HT-29 human colon cancer cells (Cho, 2013). KMF additionally inhibits the expression of various cyclins like cyclin D1 and cyclin E in breast cancer cells (Kim et al., 2016), cyclin B1 in gastric cancer cells and renal cell carcinoma (Song et al., 2014, 2015) cyclin D, cyclin E and cyclin A in colon cancer cells (Cho, 2013) and cyclin-dependent kinases like CDK4 and CDK2 (Cho, 2013). KMF treatment has also been known to up-regulate the CDK inhibitors including p21 and p27 (Fig. 4). Furthermore, results of these studies demonstrate that KMF-dependent arrest of G0/G1 or G2/M transition is possibly due to inhibition of epidermal growth factor receptor (EGFR) activity.
hexokinase-2 expression (Yao et al., 2016), inhibition of the activity of estrogen (Kim et al., 2016) or uptake of glucose (Azevedo et al., 2015). Of note, growth factors, hormones, glucose and hexokinases are positive regulators of cell cycle.

A large body of evidence indicates that KMF induces cancer cells apoptosis by activating the apoptosis-related signaling pathways (Fig. 5). Xu, Liu, Li, Wu, and Liu (2008) have indicated mitochondria in human cervical cancer cells (Hela cells) and HEK293 cells (embryonic kidney cells) as the source of KMF-dependent activation of intrinsic apoptotic signaling (Xu et al., 2008). Further, studies by Kang et al. (2009) have substantiated that KMF could cause apoptosis MCF-7 breast cancer cells with estrogen receptor (ER) by activating intrinsic apoptosis signaling pathway and by down-regulation of PLK1 expression (Kang et al., 2009). Similarly, Song et al. (2015) have shown that in gastric cancer cells KMF decreases the expression level of an anti-apoptotic protein Bcl2 on the mitochondrial membrane and concomitant induction of pro-apoptotic protein Bax release from mitochondria (Song et al., 2015). Very recently, by utilizing a number of cancer cell lines, including human breast carcinoma (MCF-7) cells, human stomach carcinoma (SCC-7901) cells, human cervical carcinoma (Hela) cells and human lung carcinoma (A549) cells Liao et al. have attested that mitochondrial dysfunction is the major reason of KMF-dependent apoptosis induction in these cancer cells (Liao et al., 2016). However, a number of other independent studies claimed that TNF cognate apoptosis-inducing ligand (TRAIL) is related to KMF-dependent apoptosis in cancer cells. Of note, the proinflammatory cytokine TNF-α and TRAIL are cognate to the activation of extrinsic apoptosis signaling pathway. For example, Yoshida et al. (2008), have shown that KMF-dependent apoptosis in colon cancer cell lines is mediated by inducing TRAIL (Yoshida et al., 2008). Likewise, TRAIL-KMF, mediated apoptosis is the result of suppression of survivin in human glioma cells (Siegelin, Reuss, Habel, Herold-Mende, & von Deimling, 2008). Besides, KMF may also affect and inhibit various pro-survival molecules, i.e. Akt, PI(3)K, ERK 1/2 in the downstream signaling pathways (Kim et al., 2016; Kuo et al., 2015). KMF also suppresses cancer metastasis in osteosarcoma cells (Chen et al., 2013) and induces autophagy (programmed cell survival) in human hepatic cancer cells (Huang et al., 2013). It has been shown that carcinoma cells activate AMP-activated protein kinase-dependent autophagy as the survival response to KMF-mediated energetic impairment (Filomeni et al., 2010). In summary, KMF decreases the number of various cancer cells through a multiprong mechanisms that include the arrest of the cell cycle, activation of proapoptotic proteins, inhibition of anti-apoptotic proteins and by attenuating the phosphorylation and activity of prosurvival proteins (e.g. Akt) and activation of programmed cell survival or autophagy.
3.2. Anti-angiogenesis effect of kaempferol

Cancer cells exhibit high metabolic rate to fulfil their energy requirements that in turn is found to be associated with the neovascularization (angiogenesis). A number of studies have reported the involvement of a variety of transcriptional (ERK 1/2, Akt, and MAPK) and growth factors (VEGF and FGF) in the tumour microenvironment for the neovascularization (Kashyap, Rajkumar Mondal, Tuli, Gaurav Kumar, & Sharma, 2016; Kashyap, Sonam Mittal, Sak, Singhal, & Tuli, 2016; Kashyap, Tuli, & Sharma, 2016; Kumar, Mittal, Sak, & Tuli, 2016; Tuli, Sandhu, Sharma, & Gandhi, 2014). These factors are being targeted as therapeutic approach for the cure of cancer in advanced stages (Fig. 6). Treatment of Huh7 cell with KMF under hypoxic (low oxygen tension) condition inhibits the HIF-1α protein through the inactivation of p44/42 MAPK pathways which could be possible ways of cancer inhibition (Mylonis, Lakka, Tsakalof, & Simos, 2010). In a study conducted by Luo et al. (2009) using human ovarian cancer cells, they suggested that KMF can inhibit angiogenesis significantly by altering the VEGF expression through both HIF dependent and independent (ESRRA) pathways (Luo et al., 2009). In context to their previous studies Luo et al. (2012a, 2012b) and Luo, Rankin, Juliano, Jiang, and Chen (2012) further proposed a novel angio-prevention mechanism of KMF via down-regulation of ERK-NFκB-cMyc-p21-VEGF signaling pathway (Luo et al., 2012a, 2012b) and Luo, Rankin, Juliano, Jiang, and Chen (2012) further proposed a novel angio-prevention mechanism of KMF via down-regulation of ERK-NFκB-cMyc-p21-VEGF signaling pathway (Luo et al., 2012a, 2012b) and Luo, Rankin, Juliano, Jiang, and Chen (2012).

Fig. 3. Schematic representations of methods for chemical synthesis of KMF. (A) Synthesis from 2,4,6-trimethoxyacetophenone; (B) Synthesis from ω-benzoxyloxyphloracetophenone.
angiogenic receptors. Fig. 6 summarizes the various above discussed molecular targets of KMF in the inhibition of cancer angiogenesis and further research is required to explore the remaining details of its mechanisms of action.
3.3. Anti-metastasis effect of kaempferol

Metastasis is considered as a hallmark of uncontrolled proliferation of the tumour cells at primary site followed by the invasion to the nearby tissue and invasion to the distant organs via bloodstream. The EMT proteins (Epithelial-Mesenchymal-Transitions), such as E-cadherin, vimentin, fibronectin, matrix metalloproteases (MMPs) are known to play a paramount role in the process of metastasis by trailing the cell-cell contacts (Short, Suarez-Zayas, & Gomez, 2016; Tulotta et al., 2016; Zhu, Guo, Wu, & Wei, 2016). Therefore, EMT proteins are considered as promising targets to combat tumour metastasis. The STAT3 is another most widely studied transcription factor associated with cancer metastasis and survival which has been found to be suppressed by KMF treatment in human prostate cancer cells (DU145) (Kwon, Kang, Kang, & Yoon, 2010). In a study by Chen et al. (2013), the anti-metastatic effect of KMF in human osteosarcoma cells (OS) was investigated by inhibiting the DNA binding activity of a transcription factor called activator protein (AP-1) which resulted in reduced expression of MMP-2 & 9 (Chen et al., 2013). Moreover, the other associated molecules, including ERK 1/2 and p38 were also found to be down-regulated under KMF treatment (Fig. 6). Similarly, ERK 1/2-mediated down-regulation of MMPs has observed in KMF-treated human tongue squamous cancer cells (SCC4) (Lin et al., 2013). In another study, KMF suppressed the transforming growth factor-β1 (TGF-β1) induced human non–small cell lung cancer (NSCLC, A549) transition from epithelial-to-mesenchymal (EMT) and migration by abolishing Akt1-mediated Smad3 phosphorylation (Eunji, Park, Choi, Jeon, & Kim, 2015). Correspondingly, Hang, Zhao, Chen, Sun, and Zhang (2015) observed the modulation of EMT-cognate proteins, including E-cadherin and vimentin in KMF-treated non-minuscule lung cancer cells (Hang et al., 2015).

3.4. Anti-inflammatory effect of kaempferol

Inflammation is known to be adopted by the tissues against various endogenous and exogenous pathogens. However, chronic inflammation has been considered to be associated with the progression of various diseases, including cancer, arthritis, and neurodegeneration (Tuli, Chaudhary, Beniwal, & Sharma, 2015; Tuli, Kashyap, Bedi, et al., 2015; Tuli, Kashyap, Sharma, & Sandhu, 2015). KMF has been proven to be a potent inhibitor of pro-inflammatory molecules such as inducible nitric oxide synthase (iNOS), cyclooxygenase (COX), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Kong, Luo, Li, Zhou, & He, 2013a, 2013b; Liu, Xiao, & Fang, 2014). The anti-inflammatory mechanisms of KMF are mainly mediated (Fig. 7) by the down-regulation of several transcription factors, such as NF-κB (nuclear factor kappa B) and STAT that have ability to stimulate the activation of inflammatory molecules (Hamalainen, Nieminen, Vuorela, Heinonen, & Moilanen, 2007). Garcia-Mediavilla et al. (2007) examined the anti-inflammatory potential of KMF in the human hepatocyte-derived cell line and proved that KMF was able to reduce the expression of C-reactive protein (CRP), COX-2, and iNOS via alterations in NF-κB pathway. Osteopontin (OPN), a reactive oxygen species (ROS)-dependent cytokine, which engenders and activates the p38 MAPK and NF-κB signaling, has been found to be down-regulated in aldosterone-induced human umbilical vein endothelial cells (HUVECs) by KMF (Liu et al., 2014). Comparably, KMF treatment in lipopolysaccharide (LPS)-induced macrophages revealed the consequential down-regulation of COX-2, iNOS and TNF-α (tumour necrosis factor-α) both at transcriptional and translational levels via inhibition of NF-κB and AP-1 transcription factor (Kim, Kim, Moh, & Kang, 2015; Kim, Park, et al., 2015). Moreover, the protein
kinase cascade mechanisms governed by Src, Syk, IRAK1, and IRAK4 that are usually involved in the activation of NF-kB and AP-1 transcriptional factors can also be blocked by KMF. The docking studies have substantiated the homogeneous binding energies of KMF as that of MG-132 which is considered to be a potent NF-

\[ \text{NF-kB} \]

\[ \text{AP-1} \]

transcriptional factors can also be blocked by KMF. The docking studies have substantiated the homogeneous binding energies of KMF as that of MG-132 which is considered to be a potent NF-kB inhibitor (Kadioglu, Nass, Saeed, Schuler, & Efferth, 2015). Therefore, evidences are suggesting that KMF may have great potential as an anti-inflammatory drug and could be introduced for in vivo trial.

### 3.5. Antioxidant properties of kaempferol

Reactive Oxygen Species (ROS) generated by enzymatic reactions during metabolism are the major source of harmful oxidative stress (Adegoke & Forbes, 2015; Hazra, Sarma, & Sanyal, 2004). Although human body has antioxidant enzymes as a defenses mechanism that constantly neutralizes the ROS, the excess concentrations of ROS become fatal and cause cellular dysfunction, oxygen toxicity, senescent, stroke, autoimmune diseases, cancer, Parkinson’s disease, infection and arteriosclerosis (Adegoke & Forbes, 2015; Melo et al., 2015). Studies have been performed using various functional foods with antioxidant agents that may be availed to dispense ROS (Gao, Yang, & Xu, 1999; Kim et al., 2003). These results showed that flavonoids could be effective secondary metabolites against oxidative stress (Yoshida et al., 2008). KMF directly scavenges peroxynitrite (reactive nitrogen species) and hydroxyl radicals at low concentration whereas at high concentrations it enhances the expression of antioxidant enzymes (Calderon-Montano et al., 2011). The proposed mechanisms of action of KMF as a potent antioxidant have been reported to be associated with its up-regulatory effect on antioxidant response elements (ARE)-mediated antioxidative enzymes (Fig. 8), such as heme oxygenase, catalase and superoxide dismutases (SODs) under the control of Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathways (Saw et al., 2014). KMF can also be utilized in the inhibition of platelet aggregation and LDL (Low-Density Lipoprotein) oxidative susceptibility (Kowalski, Samojedny, Paul, Pietsz, & Wilczok, 2005). Choe et al. (2012) extracted and purified KMF from the roots of *Rhodiola sachalimensis* and anticipated its antioxidant potential (Choe et al., 2012). Similarly, Wahab et al. (2014) extracted KMF from the beans of *Cassia alata* to study its antioxidant properties. KMF has additionally been found to bulwark myocardial ischemia/reperfusion (I/R) injury in rats by incrementing the calibers of SOD and decrementing the activity of P-GSK-3β (Zhou et al., 2015). In a study, utilizing 1,2-dimethyl hydrazine induced male Wistar rats, Nirmala and Ramanathan (2011) investigated that KMF treatment not only lowered down the erythrocyte lystate and thiobarbituric acid reactive substances (TBARS) but additionally up-regulated the antioxidant enzymes, including catalase, SOD, and glutathione peroxidase (Gpx) levels (Nirmala & Ramanathan, 2011). Likewise, hepatoprotective effect of KMF glycosides has been investigated against...
carbon tetrachloride-induced liver injuries in mice by uplifting the oxidative stress scavenging potential (Wang, Sun, Jiang, Xie, & Zhang, 2015; Wang, Tang, & Zhang, 2015). In osteoblast-like MC3T3-E1 cells, KMF inverted the antimycin A (AMA)-induced toxicity by averting the disruption of mitochondrial membrane potential and accumulation of intracellular calcium ions and ROS via PI3K-Akt-CREB pathway (Choi, 2011).

### 3.6. Synergistic and other therapeutic effects of kaempferol

Data about phytochemicals have proved that the synergistic properties of different flavonoids may not only be utilized to enhance the potential of chemotherapeutic drugs, but also to reduce the ineluctable side effects (Kumar et al., 2015; Tuli, Kumar, Sandhu, Sharma, & Kashyap, 2015; Tuli, Sharma, Sandhu, & Kashyap, 2013). In this scenario, KMF could act as a promising molecule to boost the therapeutic potential of the chemotherapy by refining the pharmacokinetics as well as by subsisting side effects of the therapy. A coalescence of quercetin, kaempferol and naringenin was found to be significantly more efficacious antiproliferative agent against mouse liver cancer cells Hepa-1c1c7 and human prostate cancer cells LNCaP (Campbell, King, Harmston, Lila, & Erdman, 2006). In a study utilizing male SD rat models, Xu, Yang, Zheng, Zhu, and Zhu (2006) observed that KMF improves the pharmacokinetics of nifedipine by reducing the drug metabolic processes (Xu et al., 2006). Similarly, the pharmacokinetics of tamoxifen has also been found to be altered by KMF via inhibition of drug metabolizing enzymes, including CYP3A (Piao, Shin, & Choi, 2008). Besides inhibiting the activity of phase I CYPs enzymes, KMF additionally works as an inhibitor of multidrug resistance protein 1 (MDR1) or P-glycoproteins when co-administrated with etoposide and quercetin in rats and in human leukemic cells K562/A, respectively (Li, Li, & Choi, 2009; Yanqiu et al., 2013). The neuroprotective effects of quercetin, KMF and biapigenin have been investigated against kainate and N-methyl-D-aspartate-induced neuronal cell death by Silva, Oliveira, Dias, and Malva (2008). Utilizing ovarian cancer cell lines, Luo et al. investigated that KMF intensified the apoptotic effect of cisplatin by significantly down-regulating c-myc gene expression (Luo, Daddysman, Rankin, Jiang, & Chen, 2010). Thus, drug combinations could co-act and potentiate the control of intricate biological disorders. Besides governing these promising pharmacological effects, KMF has additionally been known to promote other organ protective effects as summarized in Table 2.

### 4. Absorption, metabolism and bioavailability of kaempferol

Although countless physiologically important functions of KMF have been described, poor bioavailability restricts its further clinical applications.

Flavonols are naturally dynamic polyphenolic compounds that are found in plants and plant-inferred nourishments of human diet. Their absorption as well as bioavailability in the blood is found to influence their ability to impact the cellular health. After intake, flavonoids undergo to metabolic processes as results of which they are enzymatically conjugated with sulphate, methyl or glycuronyl moieties. Different methodologies, including estimation of dietary intake, determination of plasma or urinary level, have been used to study the absorption and bioavailability potential of flavonoids. In the USA and Netherlands, KMF gives an important contribution to the daily consumption of flavonoids (25–33%), with a mean intake...
Table 2
Summary of a variety of therapeutic effects of kaempferol.

| S. no. | Property               | Mechanism                                                                 | Model                  | Dose              | References                        |
|--------|------------------------|---------------------------------------------------------------------------|------------------------|-------------------|-----------------------------------|
| 1      | Cardio-protection     | Increase SOD, P-GSK-3β, GSH/GSSG ratio, improve the recovery of LVDP, dp/dtmax, and decrease cleaved caspase-3, cyct-C, CK, LDH, MDA, TNF-α | Sprague-Dawley rat     | 15 mmol/L         | Zhou et al. (2015)                |
|        |                        | Decrease TNF-α, IL-6, and NF-κβ, inhibit JNK and p38 MAPK, inhibit Akt and Bax and Caspase-3, increase Bcl-2 and activate ERK1/2, prosurvival kinase | Wistar rat             | 20 mg/kg          | Kapil et al. (2016)               |
|        |                        | Activate BMP signaling pathway, induces miR-21 expression, downregulates DOCK4, 5, and 7 and antagonizes the PDGF-mediated pro-migratory effect | VSMC cells             | 50 μM             | Kim et al. (2015)                 |
|        |                        | Inhibit intrinsic and extrinsic pathways of apoptosis, and regulate SIRT1 expression | Rat                    | 15 mM             | Guo et al. (2015)                 |
|        |                        | Decrease TNF-α, IL-1β, MDA, E-SEL, ICAM-1, VCAM-1, and MCP-1, and increase serum SOD | Mice                   | 15 mM             | Minae and Minsuk (2015)           |
| 2      | Pulmonary Asthma-protection | Inhibit IRE1α-TRAF2-JNK activation, modulate AMPK activity, Glut4 expression, and improve islet β-cell mass | BALB/c mice                         | 10 mg/kg          | Sin et al. (2015)                 |
|        |                        | Modulate Tyk2-STAT1/3 signaling and increase SOD | Male New Zealand white rabbit | 20 mg/kg          | Daekeun et al. (2015)             |
|        |                        | Modulate Syk-PLC, and PKC-ERK-cPLA2-COX2 signaling in antigen-exposed mast cells | BEAS-2B cells | ≤20 μM | Gong et al. (2013) |
|        |                        | Decrease alveolar wall thickness, alveolar hemorrhage and leukocytes infiltration, reduced MPO activity, inactivate MAPKs, and NF-κβ signaling pathways | Male BALB/c mice | 100 mg/kg | Chen et al. (2012) |
| 3      | Diabetic-protection   | Modulate AMPK activity, Glut4 expression, and improve islet β-cell mass | Mice                                | 0.05%             | Hana et al. (2015)                |
|        |                        | Modulate AMPK activity, Glut4 expression, and improve islet β-cell mass | 3T3-L1 preadipocytes | 10 μM | Yun et al. (2010) |
|        |                        | Decrease the activity of Sp1 through stimulation of Sp1 phosphorylation by ERK1/2 and subsequent induction of LDLR expression and activity | HepG2 cells | 100 μM | Ochiai et al. (2016) |
|        |                        | Inhibit the phosphorylation of insulin IRS-1, Iκκ kinase α, and Iκκ kinase β | Rat | 50 or 150 mg/kg | Luo et al. (2015) |
|        |                        | Decrease activity of total ATPases, Na+/K+ ATPase, Ca2+ ATPase, and Mg2+ ATPase in erythrocytes and tissues | Wistar rat | 100 mg/kg BW | Al, Veeramani, Alsaif, and Chandramohan (2015) |
|        |                        | Inhibit α-glucosidase | – | 1.16 ± 0.04 × 10(-5) mol L-1 | Peng, Zhang, Liao, and Gong (2015) |
| 4      | Osteo-protection      | Inhibit bone marrow adipogenesis, downregulate ER, and activate ERK | Sprague-Dawley rat | 1 mg/kg | Ritu et al. (2008) |
|        |                        | Stimulate Krt-14 protein | MG-63 human osteoblasts | 50 mM | Christophe, Jean, Cécile, Alice, and Michel (2004) |
|        |                        | Enhance the expression of chondrogenic marker genes, such as collagen type I, collagen type X, OCN, Runx 2, Sox 9, induced ERK, and increase expression of BMP-2 | Osteoblast cells | 5 μM | Khedgikar et al. (2016) |
|        |                        | Decrease expressions of TGF-β1 and Smad 2/3, and increasing the expression of Smad 7 | ADTCS cells | 5 μM | Nepal, Li, Cho, Park, and Soh (2013) |
|        |                        | Inhibit STAT 3, NF-κβ activation, interleukin 1β, intercellular adhesion molecule 1, MMP 9, INOS, myeloperoxidase, and TNF-α | Male Sprague-Dawley rat | 10.0 mg/kg and 7.5 mg/kg | Lu et al. (2013) |
|        |                        | Inhibit MCP-1 production | – | – | Li and Pu (2011) |
|        |                        | Autophagic enhancement through LC3-II increase | Macrophage cell line J774.2 | 30 μM | Jan, Arkadiusz, Monika, Grynaya, and Tadeusz (2005) |
|        |                        | Increase expression of OCT-2, glial fibrillary acidic protein, phosphorylated STAT3, NF-κβ p65, and inhibitory expression of TNF-α, IL-1β, intercellular adhesion molecule 1, MMP 9, INOS, and myeloperoxidase | Rat | 30 μM | Giuseppe et al. (2012) |
|        |                        | Improve motor coordination, raise striatal dopamine, increase SOD and GSH-PX activity, and decrease content of MDA | Sprague-Dawley rats | – | Yu et al. (2013) |
|        |                        | Down-regulate TLR4, NF-κβ, p38 MAPK, JNK and AKT | Microglial BV2 cells | 10–100 mM | Park, Sapkota, Kim, Kim, and Kim (2011) |
| 5      | Neuro-protection      | – | – | – | (continued on next page) |
|        | Anti-depressant       | Modulate POMC mRNA or plasma β-endorphin | Male ICR mice, male albino mice, and Wistar rat | 500 μl/25 g, 100 and 200 mg/kg in mice and 50 mg/kg in rat | Soo, Yun, Pyung, Jin, and Hong (2010) and Hossein, Vahidehsadat, and Farzin (2007) |
| 6      | Hepato-protection     | Inhibit ENRD, activate LXR-β and suppresses SREBP-1 | Rat hepatocytes | 0.1, 1, 10 μM/L | Zhang et al. (2006a, 2006b) |
|        |                        | Attenuate the activity and expression of CYP2E1 | Mice | 150 μg/day/kg | Hoang et al. (2015) |
|        |                        | Decrease expressions of TGF-β1 and Smad 2/3, and increasing the expression of Smad 7 | BALB/c | 5, 10, 15, 20 mg/kg | Wang, Sun, et al. (2015) and Wang, Tang et al. (2015) |
|        |                        | Inhibit RANKL-mediated phosphorylation of ERK 1/2, p38, JNK MAP kinases, and expressions of c-Fos and NFATc1 | Mice | 100 μM | Cai, Zhao, Li, and Zhang (2014) |
| 7      | Arthritis-protection  | Inhibit expression of MMP-1, MMP-3, COX-2, PGE2, phosphorylation of ERK-1/2, p38, JNK, and activation of NF-κβ | RASF cells | 100 μM | Lee, Lee, Sung, and Yoo (2014) |
|        |                        | Increase the expression of Smad 3/5/8, downregulates the expression of TGF-β1, and reduces the expression of p38, JNK, and activation of NF-κβ | Male Sprague-Dawley rat | 10.0 mg/kg and 7.5 mg/kg | Lu et al. (2013) |

(continued on next page)
of 6–10 mg/day (Hertog, Hollman, Katan, & Kromhout, 1993; Sampson, Rimm, Hollman, De Vries, & Katan, 2002). Though, studies have been done concerning the assimilation of other flavonoids, like quercetin, the data on the bioavailability of KMF has still remained to elucidate. DeVries et al. (1998), conducted a 7-days study by utilizing tea and onions-based diet in a group of volunteers to quantify the concentrations of KMF in plasma and urine (DeVries et al., 1998). Their results revealed that KMF was excreted in about 2.5% of its consumed quantity which was higher than for quercetin (0.5%) after 4 h of dose ingestion. Similarly, using healthy humans as subject models, DuPont, Day, Bennett, Mellon, and Kroon (2004) have also reported the similar concentration (0.05 mM) of KMF in plasma after 4 h of intake of endive-based diet, containing up to 246 mg of KMF per kg (DuPont et al., 2004). In another study, researchers observed the KMF excreted in the circulating plasma (DuPont et al., 2004). Another form of KMF metabolite i.e. kaempferol-3-glucuronide (55–80%) was subjected to basic phase II metabolic conjugation in accumulation and flavones (Nielsen et al., 1998). Like quercetin, KMF may also be known to be involved in the metabolism of KMF. In a study, Nielsen, Breinholt, Justesen, Cornett, and Dragstedt (1998), investigated the hydroxylation capability of microsomes toward flavonols and flavones (Nielsen et al., 1998). Like quercetin, KMF may also be subjected to basic phase II metabolic conjugation in accumulation with glucuronide or sulphate (Day et al., 2001). It is essential to identify KMF metabolites to know the various circulating forms of this moiety. DuPont et al. (2004), has observed the conjugated form of KMF metabolite i.e. kaempferol-3-glucuronide (55–80%) in the circulating plasma (DuPont et al., 2004). Another form of metabolite subsists as kaempferol-7-sulphate which could be due to the action of human hepatocytes (Day et al., 2001). These evidences have suggested the lesser bioavailability of KMF in the bloodstream, which needs to be improved with the aim to utilize the full therapeutic potential of KMF. Using G. biloba extract- phospholipid complexes (GBP) of KMF, Chen et al. (2010), have shown the increase in oral bioavailability of flavonoids including quercetin and KMF in a rat model (Chen et al., 2010). Similarly, Wang, Sun, et al. (2015) and Wang, Tang, et al. (2015), investigated that phospholipid complex (TPH-PC) of KMF may not only increase the bioavailability (172%) but also increase the solubility (22.0 folds) in comparison to total intake of flavonoids (Wang, Sun, et al., 2015; Wang, Tang, et al., 2015). Another approach to improve the bioavailability of the therapeutically active flavonoids is to explore the effect of the supplemented food matrix ingredients. So far, very limited data are reported about the effect of food ingredients on absorption and bioavailability of KMF. It has been found that the total absorption and bioavailability of flavonoids are

### Table 2 (continued)

| S. no. | Property                  | Mechanism                                                                 | Model                        | Dose            | References                          |
|-------|---------------------------|---------------------------------------------------------------------------|------------------------------|----------------|-------------------------------------|
| 9     | UV-protection             | Reduced CREB, c-Fos, histone H 3, and inhibit RSK2 and Mek1                | Human squamous cell carcinoma | 2.5 mg         | Ke et al. (2014)                     |
|       |                           | Suppresses COX-2 expression by blocking Src kinase activity                 | J6B P + mouse epidermal cells | 20 or 40 μM    | Kyung et al. (2010)                 |
| 10    | Ovary-protection          | Induce expression of PR regulated transcriptional targets                  | Rat                          | 20 μM          | Toh et al. (2014)                   |
| 11    | Immunosuppressant         | Increase CD4 + Foxp3 + Tregs, suppress DC maturation and their IL-6 expression | Mice                        | 0.1 mg         | Zeng et al. (2015)                  |
| 12    | Anti-parallel             | Entamoeba histolytica trophozoites, through deregulation of cytoskeleton-related protein | Chloroquine-resistant P. falciparum | 27.7 μM        | Bolaños et al. (2015)               |
|       |                           |                                                                           | P. falciparum strain, K-1   | 106 μM         | Melisa et al. (2014)                |
| 13    | Anti-viral effect         | Inactivate virus by binding with JEV 5sRNA                                 | Virus-infected BHK21 cells   | 25 mM          | Ting et al. (2012)                  |
|       |                           |                                                                           | PBMCs                        | 100, 50, 25 and 10 μg/ml | Bebbabani, Sayedipour, Pourazar, and Shanelhasszhadeh (2010) |
| 14    | Anti-fungal               | Coronavirus by targeting 3a channel                                        | Xenopus oocyte EV71 isolate | 20 μM          | Schwarz et al. (2014)               |
|       |                           |                                                                           | C. albicans z2003            | 35 μM          | Tsai et al. (2011)                  |

Foot Note - SOD (Superoxide dismutase), P-8SK-3 (Glucose Synthase Kinase 3), LVDP (Left Ventricular Developed Pressure), cyt-C (cytotoxic-c), CK (Creatine kinase), LDH (Lactate dehydrogenase), MDA (Malondialdehyde), TNF-x (Tumour necrosis factor-x), IL-6 (Interleukin 6), NF-κB (nuclear factor kappa-light-chain-enhanced of activated B cells), JNK (c-Jun N-terminal kinases), Bax (Bcl-2-associated X protein), Bcl-2 (B-cell lymphoma 2), Dock1, (Dedicator of cytokinesis 4), SIRT (Sirtuin 1), PDGF (Platelet-derived growth factor), CaM kinase II, (Ca2+/calmodulin-dependent protein kinase II), IL1β (Interleukin 1 beta), ICAM (Interleucellular Adhesion Molecule 1), VCAM (Vascular cell adhesion protein), MCF-1 (Mammary Chemoattractant Protein-1), COX-2 (Cylooxygenase-2), STAT1 (Signal transducer and activator of transcription 3), MPO (Myeloperoxidase), MAPK (Mitogen-activated protein kinase), AMPK (AMP-activated protein kinase), PPARY (Peroxisome proliferator-activated receptor), Sp1 (specificity protein 1), ERK (Extracellular signal-regulated kinases), Krt-14 (Keratin 14), BMP2 (Bone morphogenetic protein 2), MP3-9 (Matrix metalloproteinase 9), INOS (Inducible nitric oxide synthase), GSH-PX (Glutathione peroxidase), TRlu (Toll-like receptor 4), AKT (Protein kinase B), PR (Prostate specific antigen), CYP2E1 (Cytochrome P450 2E1), NR (Retinoid receptor), LXR (Liver X receptor), ERK (Extracellular signal-regulated kinases), Krt-14 (Keratin 14), BMP2 (Bone morphogenetic protein 2), TGF-β (Transforming growth factor beta), NFAT (nuclear factor of activated T-cells), CREB (cAMP response element-binding protein).
associated with the composition of carbohydrate based food matrix. Rodriguez-Mateos, Oruna-Concha, Kwik-Uribe, Vidal, and Spencer (2012), demonstrated that the maltitol and sucrose were found to increase and decrease the absorption of flavonoids by altering the activity of catechol-O-methyltransferease (Rodriguez-Mateos et al., 2012). Also, the methylation of flavonoids, such as genistein and KMF, appeared to modulate the metabolism as well as transportation of these wonderful molecules. Cao, Jing, Wu, and Shi (2013), indicated that the methylation of KMF not only enhances its transporting ability but also increases its hydrophobicity which further assists in the absorption, bioavailability, and binding affinity to both HSA (human serum albumin) and ovalbumin (Cao et al., 2013). Furthermore, route of administration and nanotechnology-mediated implementations in the drug delivery may also ameliorate the bioavailability of KMF. In 2009, Barve et al. reported that the half-life of KMF was 3–4 h and 1–2 h, respectively, after intravenous (10 and 25 mg/kg) and oral (100 and 250 mg/kg) dosages of KMF in male SD (Sprague-Dawley) rats (Barve et al., 2009). In a study, Luo et al. (2012a, 2012b) and Luo, Rankin, et al. (2012) observed that encapsulated poly (ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) and poly(DL-lactic acid-co-glycolic acid) drug dosages were found to be more efficacious than KMF alone (Luo et al., 2012a, 2012b; Luo, Rankin, et al., 2012). Similarly, nano-suspension of KMF was found to improve its bioavailability as well as solubility by increasing the Cmax and Area under the curve (AUC 0–2012b; Luo, Rankin, et al., 2012b) value (Qian et al., 2016). Therefore, the data confirmed the significance of bioavailability and solubility of flavonoids to exert their bioactivity and indicated that improving these important pharmacokinetic parameters may probably further enhance the biological efficacy and potential physiological capacity of KMF.

5. Epidemiological findings of studies with kaempferol-rich foods

Epidemiological studies about association between kaempferol-rich foods intake and decrease in risk of certain types of cancer have shown the variable results depending on several factors, including population type, sample size, food composition, databases used, and other concurrent lifestyle determinants.

No association between consumption of KMF and total invasive cancer risk was found among middle-aged and older women in the Women’s Health Study (Wang et al., 2009). However, among 66,940 women included in the Nurses’ Health Study, Gates et al. observed a significant (40%) reduction in ovarian cancer incidence for the highest versus the lowest quintile of KMF intake (Gates et al., 2007). On the other hand, a large-scale case-control study showed non-significant (21%) reduction in the incidence of ovarian cancer among women who were at highest quintile of KMF intake (Gates et al., 2009). Similarly, a non-significant (27%) decrease in ovarian cancer risk was noted to be associated with a high KMF intake in a rather small case-control study (124 ovarian cancer cases and 696 population-based controls) conducted in the western New York (McCann, Freudenheim, Marshall, & Graham, 2003).

In addition, there was no evidence showing a relationship between KMF intake and breast cancer risk described in the Nurses Health Study II (Adebamowo et al., 2005), whereas a low consumption of KMF was significantly associated with decreased risk of estrogen receptor (ER) negative-neoplasias compared to ER-positive tumour among premenopausal women (Touilaud et al., 2005). An inverse association of KMF intake with advanced stage (stage III/IV or stage IV, but not non-advanced) prostate cancer in the Netherlands Cohort Study was also described (Geybels et al., 2013). Although there was no remarkable relationships between high KMF intake and colorectal cancer risk among women from the Nurses’ Health Study and men from the Health Professionals Follow-Up Study (Lin et al., 2006), a statistically significant reduction in the risk of advanced adenoma recurrence was observed in Polyp Prevention Trial (Bobe, Sansbury, et al., 2008). Furthermore, consumption of higher dose of KMF was found to be protective against gastric cancer in a case-control study conducted in the Spain (Garcia-Closas, Gonzalez, Agudo, & Riboli, 1999). KMF intake was also significantly associated with decreased risk of pancreatic cancer among current smokers (but not among never or former smokers) in the large Multiethnic Cohort Study with participants from Hawaii and California (Nothlings, Murphy, Wilkens, Henderson, & Kolonel, 2007) and among male smokers who were not consuming supplements of vitamin E or β-carotene in the α-Tocopherol, β-Carotene Cancer Prevention Study (Bobe, Weinstein, et al., 2008). Moreover, high intakes of KMF were inversely associated with the development of lung tumour in a case-control study carried out in Los Angeles County, manifesting only among tobacco smokers and not among non-smokers (Cui et al., 2008). The data of a case-control study of lung cancer in women in Spain exhibited a non-significant association for the lowest vs. lowest tertile intake of KMF (Garcia-Closas, Agudo, Gonzalez, & Riboli, 1998).

Consequently, in the above-presented findings, consuming KMF rich diet may be related to lower cancer risk which could be feasible in specific tumour types and in certain populations. More epidemiological studies with larger cohorts are required to further investigate the potential role of kaempferol-rich foodstuffs in prevention of chronic diseases, such as cancer.

6. Conclusion and future perspectives

Functional foods have always been known to upgrade health benefits due to their broad spectrum of biological functions and interactions. Evidences have suggested the salutary effects of dietary KMF in plummeting the peril of lethal diseases, such as cancer. Current chemotherapeutic agents are known to pose serious health risks which could be solved by utilizing natural bioactive metabolites like KMF. However, the scientific community should always endeavour to ameliorate the potency of such wondrous molecules. As the structure of KMF revealed the availability of electron donor atoms, such as oxygen which can make the co-ordinate bond with metal atoms and resulting metal complexes of KMF may further boost its biological activity (Kashyap, Rajkumar Mondal, et al., 2016; Kashyap, Sonam Mittal, et al., 2016; Tuli, Sandhu, & Sharma, 2014). Computational implements like QSAR models can be acclimated to explore the unknown molecular interactions of KMF with recognized cellular receptors (Bose, Michael, Prashanth, & Chitraa, 2015). Synergistic amalgamations with other promising natural bioactive molecules could also be visually perceived as another prospective of future study to enhance the therapeutic potential of KMF (Tuli, Kashyap, & Sharma, 2015). Moreover, the role of KMF in modulating the expression and activity of drug metabolizing enzymes, such as CYPs could also avail the scientific communities to come forward to design novel strategies with subsisting chemotherapeutic agents (Bibi, 2008; Huang, Liangli, & Thomas, 2014; Zhang, Zheng, Zhu, Shen, & Zhu, 2006a, 2006b). Such approaches might be auxiliary in reducing the KMF-associated toxic (Canada, Watkins, & Nguyen, 1989; Silva et al., 1997) effects by lowering the requisite of active dosages. Furthermore, novel derivatives of KMF could additionally be an option to ameliorate the potency as well as dose-associated toxicity of this molecule. Rho and his colleagues have designed KMF predicated rhamnosides and purposed them as a paramount moiety in the obviation of inflammatory disorders (Rho et al., 2011). Lower potency of a drug has also been found to be associated with its
poor solubility and low bioavailability that can further be amended by utilizing the modern nanotechnology implements (Kuldeep & Ganju, 2014; Pinho, Martin, Graca, & Mariana, 2014, Luo et al. (2012a, 2012b) and Luo, Rankin, et al. (2012), have designed a novel nano-formulation for KMF utilizing Poly DL-lactic acid-co-glycolic acid, nanoparticles with amended bioavailability and cytotoxic effect against ovarian cancer (Luo et al., 2012a, 2012b; Luo, Rankin, et al., 2012). Moreover, the acerbic and astringent taste of most of the flavonoids could additionally be overcome by utilizing the nanotechnology mediated encapsulation processes which may further enhance their applicability on the more astronomically immense scale in aliment items (Munin and Edwards-Ley, 2011). Thus, KMF could prove to be a promising therapeutic agent and is certainly worth of further molecular studies.

Conflict of interest
None.

Acknowledgement
Authors are equally thankful to the department of Histopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab and Maharishi Markandeshwar University, Mullana for providing the requisite facility to carry out the work.

References
Adebanwo, C. A., Cho, E., Sampson, L., Katan, M. B., Spiegelman, D., Willett, W. C., & Holmes, M. D. (2005). Dietary flavonoids and flavonoid-rich foods intake and the risk of breast cancer. International Journal of Cancer, 114, 628–633.
Adegbe, O., & Forbes, P. B. C. (2015). Challenges and advances in quantum dot applications. Chemistry, 11(4), 298–344.
Akiyama, T., Yamaguchi, Y., & Ikeda, Y. (2014). The chemopreventive effect of the dietary compound kaempferol on the pro-inflammatory cytokines and human health and cancer chemoprevention. Food Chemistry, 138, 2099–2107.
Chen, H. J., Lin, C. M., Lee, C. Y., Shih, N. C., Peng, S. F., Tsuizuki, M., ... Yang, J. S. (2013). Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and Akt signaling pathways in U-2 OS human osteosarcoma cells. Oncology Report, 30(2), 925–932.
Chen, Z. P., Sun, J., Chen, H. X., Yao, X. Y., Liu, D., Chen, J., ... Cai, B. C. (2010). Comparative pharmacokinetics and bioavailability of quercetin and kaempferol and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats. Food and Chemical Toxicology, 48(6), 1666–1700.
Choe, K., Kwon, J. H., Park, K. H., Oh, M. H., Kim, M. H., Kim, H. H., ... Lee, M. W. (2012). The antioxidant and anti-inflammatory effects of phenolic compounds isolated from the root of Rhodiola sachalinensis A. BOR. Molecules, 17, 11484–11494.
Choi, E. M. (2011). Kaempferol protects MCF7-E1 cells through antioxidant effect and regulation of mitochondrial function. Food and Chemical Toxicology, 49(8), 1800–1805. http://dx.doi.org/10.1016/j.fct.2011.04.031.
Christophe, P., Jean, C. M., Cécile, M., Alice, W., & Michel, B. (2004). Stimulation effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor beta signaling pathway. Biochemistry and Molecular Biology Education, 32, 130–133.
Cui, Y., Morgenstern, H., Greenland, S., Tashkin, D. P., Mao, J. T., Cai, L., ... Zhang, Z. F. (2008). Dietary flavonoid intake and lung cancer – A population-based case-control study. Cancer, 112, 2241–2248.
Daekeun, S., Sin, H Park., Yeon, J. C., Yun, H K., Lucia, A. D., Nurnia, U. H., ... Young, H. K. (2015). Dietary compound kaempferol inhibits airway thickening induced by allergic reaction in a bovine, serum albumin-induced model of asthma. International Journal of Molecular Science, 16, 29980–29992.
Ding, Q., Song, W., Xu, D., Ma, Y., Li, F., Zeng, J., ... Li, L. L. (2015). Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Molecular Carcinogenesis, 54(9), 831–840.
Daito, H., Itoh, A., Akada, I., Dus, C., R. N., Faulls, C. B. R., ... Williamson, G. (2000). Dietary flavonoids and isoflavone glycosides are hydrolysed by the lactase site of lactose phosphorylase. FEBS Letters, 456(1–3), 166–170.
Dai, A. J., Mei, J. M., DuPont, M. S., Johnson, L. T., & Williamson, G. (2003). Absorption of quercetin-3-glucoside and quercetin-4-glucoside in the rat small intestine: The role of lactase phosphatase hydrolysis and the sodium-dependent glucose transporter. Biochemical Pharmacology, 65, 1199–1206.
Day, A. J., Mellon, F., Barron, D., Sarrazin, G., Morgan, M. R. A., & Williamson, G. (2001). Human metabolism of dietary flavonoids: Identification of plasma metabolites of quercetin. Free Radical Research, 35, 941–952.
Devi, K. P., Malar, D. S., Nabavi, S. F., Sureda, A., Xiao, J., Nabavi, S. M., & Daglia, M. (2015). Kaempferol and quercetin: Metabolism and pharmacology: From chemistry to medicine. Pharmacological Research, 99, 1–10.
DeVries, J. H. M., Hollman, P. C. H., Meyboom, S., Buysman, M. N. C. P., Zock, P. L., Van Staveren, W. A., & Katan, M. B. (1998). Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. The American Journal of Clinical Nutrition, 68, 60–65.
DuPont, M. S., Day, A. J., Bennett, R. N., Mellon, F. A., & Kroon, P. A. (2004). Kaempferol-3-glucoside, in humans. European Journal of Clinical Nutrition, 58, 947–954.
Eunji, J., Park, S. J., Choi, Y. S., Jeon, W. K., & Kim, B. C. (2015). Kaempferol suppresses transforming growth factor-β1–Induced Epithelial-to-Mesenchymal transition and migration of A549 lung cancer cells by inhibiting AKT1-mediated Phosphorylation of Smad3 at Threonine-1781. Neoplasia, 17(7), 525–537.
Filomeni, G., Desideri, E., Cardaci, S., Graziani, I., Piccirillo, S., Rotilio, G., & Cirillo, M. R. (2010). Carcinoma cells activate AMP-activated protein kinase-dependent autophagy as survival response to kaempferol-mediated energetic impairment. Autophagy, 6(2), 202–216.
Gao, Z., Yang, W. X., & Xu, H. (1999). Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Gen. Biochemical et Biophysica Acta—General Subjects, 1472(3), 643–650.
Garcia-Closas, R., Agudo, A., Gonzalez, C. A., & Riboli, E. (1998). Intake of specific carotenoids and flavonoids and the risk of lung cancer in women in Barcelona, Spain. European Journal of Cancer Prevention, 7, 15–19.
Garcia-Closas, R., Gonzalez, C. A., Agudo, A., & Riboli, E. (1999). Intake of specific carotenoids and flavonoids and the risk of gastric cancer in Spain. Cancer Causes and Control, 10, 71–75.
Garcia-Medialdea, V., Crespo, I., Collado, P. S., Esteller, A., Sanchez-Campos, S., Tumon, M. J., & Gonzalez-Gallego, J. (2007). The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. European Journal of Pharmacology, 557(2–3), 221–229.
antiproconvulsant activity on human cancer cells. European Journal of Medicinal Chemistry, 114, 24–32.

Lin, C. W., Chen, P. N., Chen, M. K., Yang, W. E., Tang, C. H., Yang, S. F., & Hsieh, Y. S. (2017). Kaempferol reduces matrix metalloproteinase-2 expression by down-regulating ERK1/2 and the activator protein-1 signaling pathways in oral cancer cells. PLoS ONE, 8(11), e80883. http://dx.doi.org/10.1371/journal.pone.0080883.

Lin, J., Zhang, S. M., Wu, K., Willett, W. C., Fuchs, C. S., & Giovannucci, E. (2006). Flavonoid intake and colorectal cancer risk in men and women. American Journal of Epidemiology, 164, 644–651.

Liu, Z. K., Xiao, H. B., & Fang, J. (2014). Anti-inflammatory properties of kaempferol via the inhibition of aldosterone signaling and aldosterone-induced gene expression. Canadian Journal of Physiology and Pharmacology, 92(2), 117–123. http://dx.doi.org/10.1139/cjp-2013-0298.

Lu, Y., Chu, C., Liang, F. W., Xi, K., Le, L., Hao, Z., & Jun, R. D. (2013). Neuroprotective effect of kaempferol glycosides against brain ischemia and neuroinflammation by inhibiting the activation of NF-kB and STAT3 in transient focal stroke. PLoS ONE, 2, e55839.

Luo, H., Daddysman, M. K., Rankin, G. O., Jiang, B. H., & Chen, Y. C. (2010). Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell International, 10, 16. http://dx.doi.org/10.1186/1475-2867-10-16.

Luo, H., Jiang, B., Li, B., Li, Z., Jiang, B. H., & Chen, Y. C. (2012a). Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. International Journal of Nanomedicine, 7, 3951–3959.

Luo, H., Jiang, B., Li, B., Li, Z., Jiang, B. H., & Chen, Y. C. (2012b). Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFkB-cMyc-p51 pathway. Food Chemistry, 130(2), 321–328. http://dx.doi.org/10.1016/j.foodchem.2012.04.045.

Luo, H., Rankin, G. O., Li, Z., Depriest, L., & Chen, Y. C. (2011). Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. Food Chemistry, 128(2), 513–519.

Luo, H., Rankin, G. O., Liu, D., Daddysman, M. K., Jiang, B. H., & Chen, Y. C. (2009). Kaempferol Inhibits Angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutrition and Cancer, 61(4), 554–563. http://dx.doi.org/10.1080/01635580802666281.

Luo, C., Yang, Y., Yang, T., Cao, C., Kong, L., He, H., & Zhou, Y. (2015). Kaempferol alleviates insulin resistance via hepatic IKK/NF-kB signal in type 2 diabetic rats. International Immunopharmacology, 28, 744–750.

McCann, S. E., Frederickson, J. L., Marzilli, R. A., & Chrambach, S. (2003). Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. Journal of Nutrition, 133, 1937–1942.

Melisa, B., Eka, W. S., Rizky, A., Ajeng, D., Toshimitsu, H., Junko, N. S., ... Hiroshi, K. (2013). Biological activities of Kaempferol: Effect of biological activities of Kaempferol on human cancer cells. In W. Herz, H. Grisebach, G. W. Kirby, & C. Fougere (Eds.), 235–243. pharmaeutics3040793.

Menezes, S. A., Silva, B., Oliveira, P. J., Dias, A., & Malva, J. O. (2008). Quercetin, kaempferol and baicalein from Hypericum perforatum are neuroprotective against excitotoxic neurotoxicity. European Journal of Pharmacology, 58, 391–397. http://dx.doi.org/10.1016/j.ejphar.2008.02.009.

Munin, A., & Edwards-Ley, F. (2011). Encapsulation of natural polyphenolic compounds; a review. Pharmaceutics, 3(4), 793–822. http://dx.doi.org/10.3390/pharmaceutics3040793.

Murakami, T., & Tanaka, N. (1988). Occurrence, structure and taxonomic implications of Firmicutes constituents. In W. Herz, G. Grisebach, G. W. Kirby, & C. Fougere (Eds.), Progress in the Chemistry of Organic Natural Products (Vol. 54, pp. 1–329). New York: Springer-Verlag.

Mylonis, I., Lakkas, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Mylonis, I., Lakka, A., Tsakalof, A., & Simos, G. (2010). The dietary flavonoid Myl...
